Therefore, we set out to further define the role of Hh signaling in CP-CML and determine if inhibition of Hh signaling, most easily achieved through inhibition of SMO, using the SMO inhibitor LDE225 was an effective strategy to target CP-CML LSC. Here, SMO is linked to chronic myelogenous leukemia, BCR-ABL1 positive.